Parsatuzumab

Drug Profile

Parsatuzumab

Alternative Names: Anti-EGFL7 - Genentech; M-444A; M0444A; MEGF-0444A; RG-7414; RO-5490248

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Genentech
  • Developer Chugai Pharmaceutical; Genentech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action EGFL7 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 17 Oct 2013 Discontinued - Phase-I for Solid tumours (combination therapy, late-stage disease, second-line therapy or greater) in USA (IV)
  • 17 Oct 2013 Discontinued - Phase-I for Solid tumours (monotherapy) in USA (IV)
  • 17 Oct 2013 Discontinued - Phase-I for Solid tumours in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top